Cited by 141Pancreatic function and diabetesRegulation of Appetite and ObesityDiabetes Treatment and Management

Ghrelin Directly Stimulates Glucagon Secretion from Pancreatic α-Cells

Open access
Chuang, Jen-Chieh, Sakata, Ichiro, Kohno, Daisuke, Perello, Mario, Osborne-Lawrence, Sherri, Repa, Joyce J., Zigman, Jeffrey M.·2011·Molecular Endocrinology

Abstract

Previous work has demonstrated that the peptide hormone ghrelin raises blood glucose. Such has been attributed to ghrelin's ability to enhance GH secretion, restrict insulin release, and/or reduce insulin sensitivity. Ghrelin's reported effects on glucagon have been inconsistent. Here, both animal- and cell-based systems were used to determine the role of glucagon in mediating ghrelin's effects on blood glucose. The tissue and cell distribution of ghrelin receptors (GHSR) was evaluated by quantitative PCR and histochemistry. Plasma glucagon levels were determined following acute acyl-ghrelin injections and in pharmacological and/or transgenic mouse models of ghrelin overexpression and GHSR deletion. Isolated mouse islets and the α-cell lines αTC1 and InR1G9 were used to evaluate ghrelin's effects on glucagon secretion and the role of calcium and ERK in this activity. GHSR mRNA was abundantly expressed in mouse islets and colocalized with glucagon in α-cells. Elevation of acyl-ghrelin acutely (after sc administration, such that physiologically relevant plasma ghrelin levels were achieved) and chronically (by slow-releasing osmotic pumps and as observed in transgenic mice harboring ghrelinomas) led to higher plasma glucagon and increased blood glucose. Conversely, genetic GHSR deletion was associated with lower plasma glucagon and reduced fasting blood glucose. Acyl-ghrelin increased glucagon secretion in a dose-dependent manner from mouse islets and α-cell lines, in a manner requiring elevation of intracellular calcium and phosphorylation of ERK. Our study shows that ghrelin's regulation of blood glucose involves direct stimulation of glucagon secretion from α-cells and introduces the ghrelin-glucagon axis as an important mechanism controlling glycemia under fasting conditions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/me.2011-1001

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chuang, J.-C., Sakata, I., Kohno, D., Perello, M., Osborne-Lawrence, S., Repa, J. J., & Zigman, J. M.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Departments of Internal Medicine [Divisions of Hypothalamic Research (J.-C.C., I.S., D.K., M.P., S.O.-L., J.J.R., J.M.Z.), The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9077
Corresponding author
Zigman, Jeffrey M.
Venue
Molecular Endocrinology
Published
2011-09-01
Volume
25
Issue
9
Pages
1600-1611
ISSN
  • 0888-8809 (ISSN-L)
  • 1944-9917
OpenAlex
W2014093079
Cited by
141
References
53
Citations by year
2026: 7 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 10 · 2018: 8 · 2017: 13 · 2016: 13 · 2015: 9 · 2014: 9 · 2013: 13 · 2012: 9
FWCI
10.47
Type
journal article
Language
en
Open access
Locations
  • Molecular Endocrinology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (5RL1DK08118504, RL1DK081185, R01DK071320, K08DK068069, 5R01DK07132006)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
ghrelin, glucagon secretion, alpha cells, growth hormone secretagogue receptor, acylated ghrelin, blood glucose regulation, fasting blood glucose, intracellular calcium, ERK1/2 phosphorylation, pancreatic islets, insulin sensitivity
MeSH terms
Animals, Blood Glucose, Calcium, Cell Line, Enzyme Activation, Glucagon, Injections, Subcutaneous, Male, Mice, Inbred C57BL, Mice, Transgenic, Down-Regulation, Extracellular Signal-Regulated MAP Kinases, Glucagon-Secreting Cells, Mice, Rats, Ghrelin, Receptors, Ghrelin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review